ArticleMedicines (Basel, Switzerland)2018
Are Long-Chain Polyunsaturated Fatty Acids the Link between the Immune System and the Microbiome towards Modulating Cancer?
Article in Medicines (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Host Dietary Nutrients Shape GH32-Mediated Microbial Responses to Prebiotic Fructans: A Randomized Trial.Foods (Basel, Switzerland) · 2025Article
- From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis.Frontiers in oncology · 2025Review
- Integrated Analysis of the Fecal Metagenome and Metabolome in Bladder Cancer in a Chinese Population.Genes · 2022Article
- Fish Oil, Se Yeast, and Micronutrient-Enriched Nutrition as Adjuvant Treatment during Target Therapy in a Murine Model of Lung Cancer.Marine drugs · 2021Article
- Omega-3 Polyunsaturated Fatty Acids and the Intestinal Epithelium-A Review.Foods (Basel, Switzerland) · 2021Review
- Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth.International journal of molecular sciences · 2020Article
- Article
- Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?International journal of molecular sciences · 2020Review
- Omega-3PUFA Attenuates MNU-Induced Colorectal Cancer in Rats by Blocking PI3K/AKT/Bcl-2 Signaling.OncoTargets and therapy · 2020Article
- The Potential Influence of the Bacterial Microbiome on the Development and Progression of ADHD.Nutrients · 2019Review
- Lipid and metabolic profiles in female dogs with mammary carcinoma receiving dietary fish oil supplementation.BMC veterinary research · 2019Article
- Marine unsaturated fatty acids: structures, bioactivities, biosynthesis and benefits.RSC advances · 2019Review
- Effect of Dietary and Supplemental Omega-3 Polyunsaturated Fatty Acids on Risk of Recurrent Gout Flares.Arthritis & rheumatology (Hoboken, N.J.) · 2019Article
- Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients.International journal of molecular sciences · 2019Review
- Nanomedicine-based formulations containing ω-3 polyunsaturated fatty acids: potential application in cardiovascular and neoplastic diseases.International journal of nanomedicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three recent studies revealed synergy between immune-checkpoint inhibitors and the microbiome as a new approach in the treatment of cancer. Incidentally, there has been significant progress in understanding the role of polyunsaturated fatty acids (PUFAs) in modulating cancer and the immune system, as well as in regulating the microbiome. Inflammation seems to be the common denominator among these seemingly unrelated biological entities-immune system, the microbiome, and long-chain polyunsaturated fatty acids (LC-PUFAs). This commentary presents a hypothesis proposing the existence of an optimal level of LC-PUFAs that nurtures the suitable gut microbiota preventing dysbiosis. This synergy between optimal LC-PUFAs and gut microbiota helps the immune system overcome the immunosuppressive tumour microenvironment including enhancing the efficacy of immune checkpoint inhibitors. A model on how LC-PUFAs (such as omega(n)-3 and n-6 fatty acids) forms a synergistic triad with the immune system and the microbiome in regulating inflammation to maintain homeostasis is presented. The principles underlying the hypothesis provide a basis in managing and even preventing cancer and other chronic diseases associated with inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.